Sandoz Faces US Denosumab Lawsuit Ahead Of Key 2025 Patent Expiry

Sandoz’s BLA Accepted For FDA Review In February; Denosumab Sales In Billions

 
• By Dean Rudge
  
Grechanyuk Aleksandr/Alamy Stock Photo
• Source: Shutterstock (Grechanyuk Aleksandr / Alamy Sto/Alamy Stock Photo)
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products